HOME >> MEDICINE >> NEWS
Even in an era of HAART Drugs, HIV patients are vulnerable to opportunistic infections

line therapy. They may not be effective, however, in patients who have previously had treatment with this class of drugs. Patients who are responding to HAART may be doing well enough that they don't need prophylaxis, she said.

"The risks versus benefits must be carefully evaluated. We want to protect patients from MAC, but we also want to prevent them from developing resistance to antibiotics," said Aberg, who is a UCSF assistant professor of medicine and also treats patients at San Francisco General.

In the pre-HAART era, macrolides were standard treatment as prevention therapy against MAC infection in AIDS patients whose CD4+ counts were below 75, according to Aberg. Now with HAART, many patients may have CD4+ counts that are higher.

The main conclusion from study findings, she said, is that careful consideration should be given to continuing use of macrolides for MAC prophylaxis when CD4+ counts have increased and to using macrolides for infection treatment if a patient has been on a macrolide previously.

Both research studies were supported by grants from the NIH UCSF Center for AIDS Research and the UC Universitywide AIDS Research Program,

In addition, the CMV retinitis study received a grant from Research to Prevent Blindness, Inc., and the macrolide bacterial resistance study received support from Abbott Laboratories.


'"/>

Contact: Corinna Kaarlela
ckaarlela@pubaff.ucsf.edu
415-476-3804
University of California - San Francisco
27-Sep-1999


Page: 1 2 3

Related medicine news :

1. Most episodes of HIV blips not clinically significant in patients receiving HAART
2. Multiple characteristics of HAART affect adherence
3. Researchers examine the use of antiretroviral therapy among injection drug users with HIV infection: Study suggests addiction treatment and health care contribute to HAART enrollment
4. ICAAC highlight: MAC prophylaxis can be safely discontinued in HIV-infected patients who respond to HAART
5. Old Drugs, New Tricks
6. Hormonal treatment improves survival in high-risk prostate cancer patients
7. Study finds that coordinating care of chronically ill patients does not increase liability
8. Mouse model reveals potential way to reduce cardiac deaths in kidney patients
9. Optical technique identifies vulnerable plaques in cardiac patients
10. NHS target driven culture is failing patients
11. Cardiac deaths peak in sleep hours for patients with sleep apnea

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... The American ... Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium ... 8. , In honor of Morris F. Collen, a pioneer in the field of ...
(Date:10/12/2017)... ... 2017 , ... Dr. Parsa Mohebi, the Los Angeles based ... the newly revamped Cosmetic Town journal section, featuring articles written by ... as Follicular Unit Extraction (FUE). , Dr. Mohebi says “I enjoy ...
(Date:10/12/2017)... ... ... On Saturday, October 21, the Health & Wellness Center at Florida Hospital ... for the American Heart Association Heart Walk. Teams of up to 10 people can ... their treadmills moving for 5 hours. Treadmills will start at 7:00 p.m. on Saturday, ...
(Date:10/12/2017)... ... October 12, 2017 , ... In the ... a year. In some states—like New York, New Jersey, Massachusetts, Texas, Virginia, Connecticut, ... retirement havens have extremely low property-tax rates, which contributes to the relatively lower ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... enhanced Pepper Flow promotional review platform at the Promotional Review Committee Compliance ... capabilities help marketers streamline the medical, legal, and regulatory review (MLR) process ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... Israel and NEW YORK , Sept. 27, ... with mobile health and big data solutions, today announced that its MyDario ... Please check your local TV listings for when The Dr. Oz Show ... ... season this month. ...
(Date:9/23/2017)... Pa. , Sept. 22, 2017 Janssen ... a complete response letter from the U.S. Food and ... seeking approval of sirukumab for the treatment of moderately ... letter indicates additional clinical data are needed to further ... moderately to severely active RA. ...
(Date:9/19/2017)... Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that uses ... today:   ... Jim ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D and business ...
Breaking Medicine Technology:
Cached News: